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Abstract
Background:  Amiloride derivatives, commonly used for their diuretic and antihypertensive
properties, can also cause a sustained but reversible decrease of intracellular pH (pHi). Using
dimethyl amiloride (DMA) on normal rodent pancreatic islets, we previously demonstrated the
critical influence of islet pHi on insulin secretion. Nutrient-stimulated insulin secretion (NSIS)
requires a specific pHi-range, and is dramatically enhanced by forced intracellular acidification with
DMA. Furthermore, DMA can enable certain non-secretagogues to stimulate insulin secretion, and
induce time-dependent potentiation (TDP) of insulin release in mouse islets where this function is
normally absent. The present study was performed to determine whether pHi-manipulation could
correct the secretory defect in islets isolated from mice with type 2 diabetes.
Methods: Using two mouse models of type 2 diabetes, we compared a) pHi-regulation, and b)
NSIS with and without treatment with amiloride derivatives, in islets isolated from diabetic mice
and wild type mice.
Results: A majority of the islets from the diabetic mice showed a slightly elevated basal pHi and/
or poor recovery from acid/base load. DMA treatment produced a significant increase of NSIS in
islets from the diabetic models. DMA also enabled glucose to induce TDP in the islets from diabetic
mice, albeit to a lesser degree than in normal islets.
Conclusion: Islets from diabetic mice show some mis-regulation of intracellular pH, and their
secretory capacity is consistently enhanced by DMA/amiloride. Thus, amiloride derivatives show
promise as potential therapeutic agents for type 2 diabetes.
Background
As is widely known, nutrient-stimulated insulin secretory
response in the pancreatic β cell consists of three distinct
components. These include: a) an initial peak (first phase)
triggered by Ca2+, b) augmentation of the Ca2+-triggered
response (second phase), and c) a memory that persists
after removal of the nutrient, causing enhancement of
subsequent secretory responses (time-dependent potenti-
ation) [1-4]. The first phase of the insulin response is ini-
tiated by ATP derived from glucose metabolism, which
leads to membrane depolarization through closure of
ATP-dependent K+ channels (KATP channels) and conse-
quent entry of extracellular Ca2+ through voltage-gated
Ca2+ channels. This influx of Ca2+ triggers the release of a
Published: 08 December 2005
BMC Endocrine Disorders 2005, 5:9 doi:10.1186/1472-6823-5-9
Received: 30 June 2005
Accepted: 08 December 2005
This article is available from: http://www.biomedcentral.com/1472-6823/5/9
© 2005 Gunawardana et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Endocrine Disorders 2005, 5:9 http://www.biomedcentral.com/1472-6823/5/9
Page 2 of 7
(page number not for citation purposes)
small pool of secretory granules, thus producing the ini-
tial peak of the insulin response [1]. This peak is followed
by a sustained second phase of insulin release that lasts
through the duration of exposure to the nutrient, medi-
ated through augmentation of the Ca2+-triggered first-
phase response [1]. Time-dependent potentiation (TDP),
a positive memory induced during this acute response,
magnifies subsequent secretory responses to all secretago-
gues [2,4-6].
Islet intracellular pH (pHi) exerts a strong influence on all
aspects of the insulin secretory response, as well as other
related functions such as Ca2+ influx and K+ retention [7-
17]. These functions are enhanced by a decrease of pHi,
and inhibited by an increase of pHi. Our recent work on
isolated mouse islets has demonstrated that NSIS requires
a specific pHi-range, and is greatly enhanced by decreasing
islet pHi using DMA [7]. The basal pHi in mouse islets
ranges from 6.9 to 7.2. Treatment with DMA, an inhibitor
of the Na+/H+ exchanger, brings islet pHi to the lower
range of 6.4–6.8. This decrease of pHi in turn causes a dra-
matic enhancement in insulin secretion induced by meta-
bolic secretagogues, and enables certain non-
secretagogues to stimulate insulin release [7]. Another
remarkable effect of DMA is to enable glucose to induce
TDP, a function normally absent in mouse islets [7].
Hence, DMA has a consistently favorable effect on all
aspects of the insulin response in isolated mouse islets.
Previous studies have shown similarly positive effects of
amiloride derivatives on insulin secretion in other species
as well [8,12-14,16].
Thus, it is possible that: a) a mis-regulation of intracellular
pH may contribute to the defect in insulin secretion found
in type 2 diabetes; and b) Forcing the islet pHi to a lower
range may correct/improve this secretory defect. To test
these hypotheses, we monitored insulin secretion and
islet pHi in two mouse models of type 2 diabetes. Regula-
tion of islet pHi and the influence of amiloride derivatives
on insulin secretion and TDP in isolated islets from dia-
betic mice were compared to similar parameters in islets
from wild type mice.
Results from both models of type 2 diabetes demonstrate
some abnormalities in pHi-regulation, and consistently
favorable effects of DMA/amiloride on both direct insulin
secretion and TDP in isolated islets. These results suggest
the potential value of amiloride derivatives in treatment
of type 2 diabetes
Methods
Animals
Mouse models of type 2 diabetes i.e. strains NON/LtJ
(Diabetic NON mice; stock number 002423) and KK/Upj-
A<y>/J (Diabetic KK mice; stock number 002468) were
purchased from Jackson Laboratories, Bar Harbor, ME.
C57BL6 mice (Harlan Sprague Dawley, Indianapolis, IN)
were used as wild type controls. All animals were males,
and the control mice were 7–9 weeks of age. The diabetic
KK and NON mice were used at 9–20 weeks and 5–9
months, respectively, in order to allow time for NIDDM to
develop. The body weight range was 20–30 g for the con-
trol mice, and 40–80 g for the diabetic mice. The animals
were fed standard laboratory chow, and cared for accord-
ing to the guidelines of the Vanderbilt Institutional Ani-
mal Care and Use Committee.
Media
Pancreatic islets were isolated in Hanks Balanced Salt
solution, and HEPES-buffered Krebs Ringer Bicarbonate
solution (KRBH) was used for the static incubations in
secretion experiments. The components of KRBH are as
follows: 128.8 mM NaCl; 4.8 mM KCl; 1.2 mM KH2PO4;
1.2 mM MgSO4; 2.5 mM CaCl2; 5 mM NaHCO3
-; 10 mM
HEPES; and 0.1% bovine serum albumin. The medium
pH was maintained at 7.4. Basal KRBH used for pre-incu-
bation and non-stimulated controls contained 2.8 mM
glucose, while the stimulating media contained either
16.7 mM glucose, or other secretagogues as indicated in
the presence of 2.8 mM glucose. The non-glucose secreta-
gogues included 20 mM alpha-ketoisocaproate (αKIC), or
20 mM 2-amino-bicyclo[2,2,1]heptane-2-carboxylic acid
(BCH).  αKIC, a mitochondrially-metabolized secreta-
gogue, is a metabolic product of the amino acid leucine.
BCH is a non-metabolizable analog of leucine, and stim-
ulates insulin secretion presumably through allosteric
activation of mitochondrial dehydrogenases. For forced
decrease of islet pHi, 40 µM DMA was added to the
medium to produce intracellular acidification. In prepara-
tion for imaging experiments, islets were cultured in RPMI
1640 culture medium supplemented with 10% heat-inac-
tivated fetal bovine serum, 100 U/ml penicillin, 0.1 g/L
streptomycin and 11 mM glucose.
Isolation of islets
A modified version of the collagenase digestion method
described by Lacy and Kostianovsky [18] was used. Mice
were terminally anesthetized with intra-peritoneal injec-
tion of Ketamine/Xylazine (80/20 mg/Kg). Pancreas was
removed, placed in ice-cold Hanks solution and minced
with scissors. Collagenase (3 mg/ml) was added and the
mixture shaken in a 37°C water bath until the tissue was
adequately digested. The mixture was then centrifuged,
supernatant removed and the pellet re-suspended in
Hanks solution. Centrifugation and re-suspension were
repeated several times to remove exocrine tissue. The final
pellet was re-suspended either in basal KRBH medium for
secretion experiments or RPMI medium for islet culture.
Islets were hand picked under a stereomicroscope.BMC Endocrine Disorders 2005, 5:9 http://www.biomedcentral.com/1472-6823/5/9
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Culture of islets
The method described by Arkhammar et al. 1998 [19] was
used with minor modifications [7,20,21]. 35 mm culture
dishes with glass-bottomed wells (Mat-Tek corporation)
were used. The dishes were pre-prepared by coating the
wells with human extracellular matrix (BD Biosciences).
Freshly isolated islets were placed carefully in each well,
covered with RPMI medium containing 11 mM glucose,
and cultured at 37°C in 95% O2 and 5% CO2. Under these
conditions, the cells in the islet spread out within 14 days,
greatly reducing the islet thickness and making it particu-
larly suitable for imaging with confocal microscopy. Islets
cultured under these conditions exhibit normal responses
of Ca2+, NAD(P)H and insulin release to glucose stimula-
tion, as described in previous studies [19-21] and con-
firmed in our preliminary experiments.
Intracellular pH measurements
As described in our previous studies [7], islet pHi was
monitored by confocal microscopy, using carboxy-semi-
naphthorhodofluor-5 (SNARF5) [22], a pH-sensitive flu-
orescent indicator. Prior to imaging, cultured islets were
maintained in RPMI medium containing 5 mM glucose
for at least 48 hours. On the day of the experiment, RPMI
medium was removed, and islets were washed and placed
in basal KRBH medium. SNARF5-AM (5 µM final concen-
tration) was added and incubated for one hour at 37°C.
Loaded islets were placed on a warmed stage in a humid-
ified and temperature-controlled chamber at 37°C, and
monitored with a F-Fluar 40 × 1.3 NA oil immersion lens
of a LSM510 confocal laser-scanning microscope (Zeiss).
Islets were excited at 514 nm with an argon laser, and the
emission fluorescence was collected in the band-widths
568–589 nm and 621–643 nm (peak emission at 580 and
630 nm) using the Meta detector (Zeiss). Time-series
images (2.56 µs/pixel) were collected for 5–20 minutes as
was suitable for each experiment. A stable baseline was
obtained before the actual recording for each experimen-
tal condition started. LSM software was used to calculate
the ratio between the two emission fluorescence values
from selected well-loaded regions in each islet. This ratio
was proportional to the islet pHi. The results were ana-
lyzed using LSM software, Graphpad Prism, and Microsoft
Excel. One representative recording for each experimental
condition is shown in the results section, and the value n
denotes the number of recordings done with different
islets for each condition. A standard curve was prepared
by fixing the islet pHi at known values (ranging from 5.5
to 9, with 5–10 islets for each pH), using a KRBH medium
containing 100 mM K+ and 20 mM nigericin to equilibrate
the pH inside and outside cells.
Secretion measurements
All incubations were done in a 37°C water bath. Freshly
isolated islets were pre-incubated for one hour in basal
KRBH containing 2.8 mM glucose. Islets were then
divided into groups and stimulated with different com-
pounds as indicated in the results section, for one hour.
Control group was maintained in basal glucose. Each
group consisted of 4–5 tubes containing 4 islets per tube.
At the end of the stimulation period, samples were col-
lected for insulin measurement by radio-immuno-assay
(performed by the DRTC Core facility at Vanderbilt Uni-
versity). Islet insulin content was measured after freezing
islets overnight in 1% Triton-X. Insulin secretion was
expressed as fractional release, i.e. the percentage of total
insulin content released over the period of stimulation. In
the experiments monitoring TDP, after pre-incubation
islets were exposed to high (16.7 mM) glucose with or
without intracellular acidification for 40 minutes, while
the control group was exposed to basal glucose. Subse-
quently all groups were rested in basal glucose for 20 min-
utes, and stimulated with high glucose for 40 minutes
prior to collection of samples for insulin assay. The value
n denotes the number of times each experiment was
repeated using islets from different mice.
In vivo treatment
Effect of oral treatment with amiloride derivatives on
insulin secretion from isolated islets was monitored in
diabetic NON mice. Mice were divided into three groups,
i.e. DMA-treated; amiloride treated; and untreated con-
trol. DMA (estimated dose: 1 mg/Kg/day) or amiloride
(estimated dose: 5 mg/Kg/day) was administered in
drinking water to the test groups for one week. At the end
of the week mice were euthanized and insulin secretion
was measured from isolated islets as described earlier.
Statistical Analysis
Values are expressed as mean ± SEM. Groups were com-
pared using paired Student's t test. In secretion studies, n
denotes the number of times each experiment was
repeated with islets from different mice. In imaging exper-
iments for pHi, n denotes the number of islets imaged for
each condition.
Results and Discussion
The influence of islet pHi on insulin secretion has been
reported in a number of studies [7-17]. Our recent work
in isolated mouse islets has demonstrated the critical
dependence of NSIS on an appropriate pHi, and the abil-
ity of pHi-lowering agents to dramatically enhance all
components of the insulin response [7]. Type 2 diabetes is
characterized by a progressive decline in insulin secretion
in the β cell in addition to peripheral insulin resistance.
Since islet pHi plays a critical role in NSIS in normal islets,
it is likely that a mis-regulation of pHi may contribute to
this secretory defect, which could be corrected through
manipulation of islet pHi. Thus, the present study was
aimed at exploring the beneficial effects of pHi-loweringBMC Endocrine Disorders 2005, 5:9 http://www.biomedcentral.com/1472-6823/5/9
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Islets from diabetic mice show abnormalities in pHi regulation Figure 1
Islets from diabetic mice show abnormalities in pHi regulation: Cultured islets loaded with SNARF5-AM were excited 
at 514 nm, and emission fluorescence was collected at 580 and 630 nm. Islet pHi was calculated from the ratio of emission flu-
orescence. Acetate (40 mM) or NH4Cl (5 mM) was added where indicated. One representative recording for each condition is 
shown. 10–20 islets were imaged for each condition. A. Wild type islets: Basal pHi range 6.9–7.1. Fast recovery from drastic 
pHi-change produced by acid or base load. B. Islets from diabetic KK mice: Basal pHi range 7.3–7.5. Recovery from acid load is 
slower. Recovery from base load is followed by overcompensation. C. Islets from diabetic NON mice: Basal pHi similar to wild 
type controls. Response to base load is slower. Recovery is from acid/base load is followed by overcompensation.
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DMA enhances insulin secretion stimulated by glucose and αKIC (alpha-ketoisocaproate), in islets isolated from both normal  and diabetic mice Figure 2
DMA enhances insulin secretion stimulated by glucose and αKIC (alpha-ketoisocaproate), in islets isolated 
from both normal and diabetic mice: Groups of islets were treated with different secretagogues with and without intrac-
ellular acidification produced by 40 µM DMA (denoted in red). Insulin secretion was measured at the end of the 60-minute 
stimulation period. Insulin secretion produced by both 16.7 mM glucose and 20 mM αKIC is significantly enhanced by intracel-
lular acidification, in all three mouse strains (n = 10; * = p < 0.001). Values in the figure are expressed as fractional release (% 
of total insulin content released over the 60-minute period). The corresponding absolute amounts (ng/ml) for each condition 
from left to right are: 0.46 ± 0.1, 4.04 ± 0.44, 6.37 ± 0.71, 3.39 ± 0.72, 31.97 ± 2.58, 46.12 ± 5.51, 7.5 ± 0.9, 22.4 ± 3.2, 29.87 ± 
5.35, 1.24 ± 0.18, 2.05 ± 0.3, 17.12 ± 2.11, 34.73 ± 4.053, 11.8 ± 1.38 and 13.76 ± 1.77.
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drugs on insulin release from isolated islets in type 2 dia-
betes.
We used two mouse models of type 2 diabetes obtained
from Jackson laboratories: the KK/Upj-A<y>/J mice (Dia-
betic KK mice) and the NON/LtJ mice (Diabetic NON
mice). Diabetic KK mice are a congenic strain developed
as a model for obesity and type 2 diabetes. They develop
obesity, hyperglycemia (300–500 mg/dl), insulin resist-
ance and hyperinsulinemia (10 ng/ml) by 8 weeks of age
[23]. Diabetic NON mice are an inbred strain, originally
developed as a control strain for the well-known IDDM
model of NOD/LtJ. NON mice are genetically related
closely to NOD mice but have a diabetes resistant MHC
haplotype H2nb1 (Kb, Anb1, Ek, Db), and are homozygous
for the retinal degeneration allele Pde6brd1. NON mice
have genes predisposing to type 2 diabetes, evidenced by
early impaired glucose tolerance and development of
maturity onset obesity and hypoinsulinemia. At 20 weeks
of age NON males exceed 40 g in body weight, with blood
glucose and insulin levels reported around 200 mg/dl and
1 ng/ml, respectively [24].
Basal intracellular pH in wild type (WT) mouse islets
ranges from 6.9 to 7.2. The strong buffering mechanisms
in the β cells ensure quick recovery from the pHi-changes
induced by treatment with a weak acid or weak base (acid/
base load) [7,8], and Fig. 1A]. Approximately 70% of the
islets isolated from diabetic mice showed abnormalities in
their pHi-regulation. In diabetic KK mice, the basal islet
pH was higher than that in WT mice (Fig. 1B). Islets iso-
lated from both diabetic strains showed slower recovery
from acid/base load, sometimes followed by overcom-
pensation (Fig. 1:B&C). Thus, type 2 diabetes is associated
with some mis-regulation of islet pHi. Regardless of
whether these abnormalities play a role in insulin secre-
tion, treatment with amiloride derivatives is likely to
improve NSIS in diabetes.
DMA enables glucose to induce TDP in islets from both nor- mal and diabetic mice Figure 4
DMA enables glucose to induce TDP in islets from 
both normal and diabetic mice: Insulin secretion in 
response to high glucose (16.7 mM) is shown, in groups of 
islets previously exposed to glucose with and without intracel-
lular acidification produced by 40 µM DMA (denoted in red). 
DMA treatment enables glucose to induce TDP both in wild 
type controls (left) and each strain of type 2 diabetes (Right). 
G = mM glucose; n = 5; * = p < 0.001 and # = p < 0.05, com-
pared with each corresponding untreated control. Values in 
the figure are expressed as fractional release (% of total insu-
lin content released over the final 40-minute period in 
response to 16.7 mM glucose). The corresponding absolute 
amounts (ng/ml) for each condition from left to right are: 
2.88 ± 0.57, 5.3 ± 0.76, 8.5 ± 0.93, 11.96 ± 2.14, 20.32 ± 6.12, 
39.68 ± 5.69, 15.2 ± 3.23, 15.79 ± 2.59, and 19.79 ± 3.41.
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DMA normally produces a dramatic increase in nutrient
stimulated insulin secretion from isolated islets [7,8]. In
this study we monitored the effect of DMA on the insulin
response to glucose and αKIC in islets isolated from dia-
betic mice. DMA consistently enhanced insulin secretion
in response to both secretagogues (glucose and αKIC), in
islets from both diabetic models as well as from WT mice
(Fig. 2).
Since  in-vitro  treatment of isolated islets with DMA
enhances NSIS, we next tested the corresponding effects of
oral administration of DMA or amiloride to diabetic mice.
Diabetic KK mice, being hyperinsulinemic, exhibited
above-normal NSIS in the in-vitro experiments. Therefore,
the in-vivo administration of amiloride was done only in
the diabetic NON mice, which exhibited a significant
impairment in NSIS. Diabetic NON mice were divided
into three groups, i.e. DMA-treated; amiloride treated; and
untreated control. DMA (1 mg/Kg/day) or amiloride (5
mg/Kg/day) was administered in drinking water to the test
groups for one week prior to isolation of islets for insulin
measurement. Mice were housed two to a cage and their
behavior was monitored. All animals were observed to
drink frequently, and drug dose was calculated using esti-
mated water intake. Islets isolated from mice pre-treated
with DMA or amiloride consistently exhibited a signifi-
cantly stronger insulin response to all three secretagogues
tested (16.7 mM glucose, 20 mM αKIC or BCH) (Fig. 3).
Thus, oral treatment with low doses of DMA or amiloride
enhances insulin release in islets from diabetic NON
mice, with no conspicuous adverse effects on fluid or
blood pressure regulation.
One problem we encountered with the diabetic NON
mice was that the basal insulin release from isolated islets
was high. Consequently the defect in NSIS was not obvi-
ous due to the elevated basal insulin release. However, the
increase in insulin release produced by high glucose in
NON mice (2 fold or less compared to basal glucose) is
much smaller than that in the other two strains (10–12
fold compared to basal glucose), and non-glucose secret-
agogues such as αKIC and BCH do not stimulate above-
basal insulin release in NON islets. Furthermore, the
increased basal insulin release found in isolated islets may
not directly translate into elevated plasma insulin,
because the islet number per pancreas is diminished in
NON mice, and the islets show abnormalities in size and
shape as well. Thus, NON mice have a marked secretory
defect, which is corrected to a significant degree by amilo-
ride derivatives.
DMA treatment also unmasks TDP, a function normally
absent in mouse islets [7]. TDP is defined as an enhance-
ment of the insulin secretory response in the β cell,
induced by a previous exposure to glucose or certain other
secretagogues. TDP can be measured by comparing the
glucose-induced insulin response in islets previously
exposed high glucose or basal glucose. As shown in figure
4, treatment with DMA enables glucose to induce TDP in
islets from both diabetic strains, albeit to a lesser degree
than in WT islets.
These results show that islets isolated from diabetic mice
exhibit some abnormalities in their pHi-regulation, and
that several aspects of their insulin response are signifi-
cantly improved by amiloride derivatives. Thus, treatment
with low doses of amiloride derivatives shows promise in
the therapy of type 2 diabetes. The next step is to deter-
mine whether these drugs can normalize blood glucose
and insulin levels. These in vivo studies will be conducted
in a more suitable model of type 2 diabetes with a more
pronounced secretory defect, with parallel in-vitro work
on human islets. Currently we are looking into suitable
rodent models of NIDDM, and one mouse model that
shows promise is the strain GKlox/w + Rip-Cre developed
by another group at Vanderbilt [25]. The current study
shows the potential value of amiloride in improving insu-
lin release in diabetes, and recently-developed better ami-
loride analogs such as pyrazinoylguanidine [26,27] may
be good candidates for correcting the secretory defect in
human diabetes.
Conclusion
This study demonstrates the presence of abnormalities in
islet pHi-regulation in type 2 diabetes, and the ability of
DMA and amiloride to significantly improve NSIS in iso-
lated islets from diabetic mice. Thus, treatment with low
doses of amiloride derivatives has potential therapeutic
value for enhancing NSIS in human diabetes, and merits
further investigation through in vivo studies.
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